Immunogenicity of 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine when administered as catch-up vaccination to children 7 months to 5 years of age

Pediatric Infectious Disease Journal

Volumn 30, Issue 8, 2011, Pages

  Vesikari, Timo ^a   Karvonen, Aino ^a   Korhonen, Tiina ^a   Karppa, Tiina ^a   Sadeharju, Karita ^a   Fanic, Aurélie ^b   Dieussaert, Ilse ^b   Schuerman, Lode ^b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

catch up vaccination; immunogenicity; pneumococcal conjugate vaccine; safety

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; TREATMENT RESPONSE; VACCINATION;

EID: 79960632859     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31821d1790     Document Type: Article

References (27)

1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195. (Pubitemid 30167436)
2. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361. (Pubitemid 36945058)
3. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409. (Pubitemid 32128672)
4. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D provide protection against otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae: a randomized double blind efficacy study. Lancet. 2006;367:740-748. (Pubitemid 43326292)
5. Lucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age(review). Cochrane Database Syst Rev. 2004:CD004977. DOI: 10.1002/14651858.CD004977.
6. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-1146. (Pubitemid 40417563)
7. Centers for Disease Control and Protection. Active Bacterial Core surveillance. Surveillance reports Streptococcus pneumoniae. Available at: http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed March 31, 2010.
8. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child. 2002;86:396-399. (Pubitemid 34596646)
9. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2002;20:S58-S67.
10. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367. (Pubitemid 38970013)
11. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2): B20-B29.
12. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746. (Pubitemid 36514704)
13. O'Brien K, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine. 2003;21:1815-1825. (Pubitemid 36428771)
14. O'Brien K, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211-1220. (Pubitemid 47580276)
15. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66-S76.
16. Concepcion N, Frasch NE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzymelinked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266-272. (Pubitemid 32217054)
17. Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with or without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356-360.
18. Poolman JT, Frasch CE, Käyhty H, et al. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17:134-142.
19. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for production and control of pneumococcal conjugate vaccines. WHO Tech. Rep Ser 2005;927(Annex 2):64-98.
20. Centers for Disease Control and Prevention and Emory University. Streptococcus pneumoniae opsonophagocytosis using differentiated HL-60 cells (Promyelocytic Leukemia Cell Line). Laboratory protocol December 20, 1999. Available at: http://www.vaccine.uab.edu. Accessed March 31, 2010.
21. Romero-Steiner S, Frash C, Concepcion N, et al. Multi-laboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10:1019-1024. (Pubitemid 37444267)
22. Henckaerts I, Durant N, De Grave D, et al. Validation of a routine pneumococcal opsonophagocytosis assays to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25: 2518-2527. (Pubitemid 46366133)
23. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28:S109-S118.
24. Prevenar European Public Assessment Report. Available at: http://www. emea.europa.eu/humandocs/Humans/EPAR/prevenar/prevenar.htm. Accessed March 26, 2010).
25. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25:312-319.
26. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502. (Pubitemid 44634693)
27. de Aristegui Fernandez J, Cos Arregui B, Zurimendi Carril A, et al. Evaluation of the safety of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months. Vaccine. 2005;23:1917-1922. (Pubitemid 40289062)